Summary & Overview
HCPCS Level II J0490: Injection, belimumab, 10 mg
HCPCS Level II code J0490 denotes a 10 mg injection of belimumab, a monoclonal antibody used in relevant autoimmune disease management. This code captures the drug supply component for belimumab when billed separately from administration services, and it is relevant for facilities and clinicians supplying infused or injected biologic therapies across outpatient and clinic settings. Nationally, accurate use of J0490 matters for drug cost reporting, payer coverage determinations, and provider reimbursement for specialty pharmaceuticals.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical context, typical sites of service, and the payer landscape affecting coverage and claims adjudication. The publication presents benchmark considerations and common billing practices tied to J0490, highlights policy updates that influence coverage of injectable biologics, and outlines clinical and administrative factors affecting coding and billing for belimumab. Technical details such as modifiers, associated taxonomies, and diagnosis mappings are addressed in dedicated sections. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0490 represents an injection of belimumab, 10 mg, a biologic therapy used in clinical settings where intravenous or subcutaneous administration of monoclonal antibodies is provided. The service type is a therapeutic drug administration for belimumab. The typical site of service includes infusion centers, outpatient hospital departments, physician offices, and specialty clinics where injectable biologic therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 34-year-old female diagnosed with systemic lupus erythematosus (SLE) with active, autoantibody-positive disease who is receiving maintenance biologic therapy. The patient presents to an outpatient infusion center for administration of belimumab via intravenous injection, billed as J0490 per 10 mg. Pre-infusion nursing assessment includes verification of identity, medication reconciliation, review of vital signs and recent laboratory tests (including complement levels and anti-dsDNA as clinically indicated), and screening for infusion reactions or infections. A physician or advanced practice provider documents the indication, recent disease activity, and consent. The infusion nurse prepares and administers the medication according to institutional protocol, monitors the patient during and after infusion for adverse reactions, and documents the product lot, dose, route, start and stop times, and any reactions. Billing reflects the administered quantity of J0490 units (10 mg each) and any applicable modifiers to indicate special circumstances (e.g., reduced services, discontinued infusion, or drug wastage). Typical site of service is an outpatient infusion clinic, infusion center, or hospital outpatient department. Typical clinical workflow steps: order verification and prior authorization, pharmacy preparation and labeling, bedside verification and administration by nursing, post-infusion monitoring, and documentation for billing and clinical records.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|